For adults with chronic liver disease (CLD) who have thrombocytopenia and are scheduled to undergo a procedure.

LIFT PLATELETS IN JUST 5 DAYS1

Help raise your patient’s platelet counts with Doptelet® (avatrombopag).1

Number of days to reach treatment goal will vary.

Doptelet Platelet Characters Admiring Plateletville Lake

About Doptelet for chronic liver disease

In 2 randomized, double-blind, placebo-controlled studies (N=435)1:

5 DAYS

With just 5 daily doses, Doptelet can help raise platelet counts.1*

50,000

Significantly more patients taking Doptelet reached a platelet count ≥50,000/μL compared to placebo.1†

2X

On average, patients taking Doptelet nearly doubled their platelet count in time for a procedure.1

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists. 

Doptelet works with the body to increase platelet counts1-3

Doptelet helps provide added protection during and after the procedure1

Significantly reduced the need for platelet transfusions or rescue procedures for bleeding up to 7 days post procedure.1‡


Use the Doptelet Scheduling Calendar to plan your patient’s dosing start date.

*A measured increase in platelet counts was observed in Doptelet treatment groups over time beginning on Day 4 post-dose, that peaked on days 10-13, decreased 7 days post-procedure, and then returned to near baseline values by Day 35.1

†On procedure day, 10 to 13 days after starting Doptelet 40 mg or Doptelet 60 mg once daily for 5 days, compared to placebo (P<0.0001; N=435).1

‡From randomization of Doptelet 40 mg or Doptelet 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (P<0.0001; N=435).1

§In pooled analysis of ADAPT-1 and ADAPT-2 (N=277).1

Mechanism of action

Doptelet works with your body to increase platelet production in chronic liver disease1

  • Doptelet is an oral thrombopoietin receptor agonist (TPO-RA). Doptelet is an oral TPO-RA that mimics TPO in the body.1
  • Thrombopoietin (TPO) is a hormone produced in the liver that acts by binding to hematopoietic stem cell receptors in the bone marrow4,5
  • When bound to these cell receptors, TPO activates the JAK-STAT signaling pathway, resulting in stem cell differentiation to megakaryocytes, leading to the production of platelets4,5
  • Doptelet acts by binding to the same receptors as the endogenous TPO, albeit at a different binding site, ultimately activating the JAK-STAT pathway, which increases platelet production4,5
  • Doptelet does not block native TPO; it allows for an additive effect to endogenous platelet production1

Watch Video

Mechanism of action

Any questions?

Our support specialists can help answer your questions about Doptelet and access options — call us at 
855-4LIFTUP (855-454-3887)
Monday–Friday 8 AM–8 PM ET.

Hot Air Balloon with 'D' Flag Carrying Three Doptelet Platelet Characters

Read about Doptelet efficacy

Significantly more patients achieved 50K platelets by procedure day with Doptelet than with placebo. Ready to see the numbers?1

VIEW EFFICACY

  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. Data on file. Doptelet ISE Tables. 2017: Sobi, Inc.
  3. Terrault N, Chen Y, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):718.
  4. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022;53:100909.
  5. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.